Results for tag: "Zemaira"

Zemaira is a market within the context of Endocrine and Metabolic Disorders Drugs. It is a recombinant human C1 esterase inhibitor (rhC1INH) used to treat hereditary angioedema (HAE). HAE is a rare, genetic disorder that causes episodes of swelling in the face, extremities, gastrointestinal tract, and airway. Zemaira is administered intravenously and works by replacing the missing C1INH protein in the body. It helps to reduce the frequency and severity of HAE attacks. The Zemaira market is composed of a number of companies that specialize in the development and production of rhC1INH. These companies include CSL Behring, Shire, ViroPharma, and Pharming Group. Each of these companies has developed their own version of rhC1INH, which is used to treat HAE. Show Less Read more